BioVentrix Appoints Jim Dillon as New Leader

BioVentrix Inc., a company focused on treating congestive heart failure (CHF) via Transcatheter-based Ventricular Restoration (TCVR), named Jim Dillon president and CEO..
 
Dillon is an experienced leader in both major cardiovascular organizations and promising start-ups. He most recently co-founded Reprieve Cardiovascular and led financing and development of a highly unique therapy for acute decompensated heart failure (ADHF). His focus in heart failure includes developing therapies to enable native heart recovery, reduce the size of a patient’s myocardial infarction, repair adult and congenital cardiac defects, and innovate personalized volume management for acutely decompensated patients.
 
Dillon joined St. Jude Medical in 2011 and held a series of corporate strategic and sales leadership positions. He was involved with multiple highly successful medical device companies as a key contributor to their acquisition and exit. Prior to joining St. Jude, Jim held senior executive sales and marketing positions with such companies as Abiomed, TherOx and InfraReDx.
 
“Jim’s field-based leadership style, combined with his proven success in building high-performance global teams, makes him the ideal candidate to lead our company,” Steven Healy, Chairman of the Board, BioVentrix said in a press release. “Jim’s knowledge and experience in market development, ability to ensure a business’s financial integrity, and his strong relationships with renowned physicians will prove highly beneficial in building BioVentrix and optimizing shareholder value. I would also like to thank Ken Miller for his years of service and many contributions to BioVentrix.”
 
“I am excited to join the BioVentrix team at a pivotal time in the company’s growth,” said Dillon. “This is a unique chance to revolutionize the treatment of congestive heart failure caused by ischemic cardiomyopathy and provide a better quality of life for countless patients worldwide.”